特异性靶向gp120或gp41的小分子HIV进入抑制剂的研发
Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41.
作者信息
Lu Lu, Yu Fei, Cai Lifeng, Debnath Asim K, Jiang Shibo
机构信息
Key Laboratory of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, 130 Dong An Road, Building #13, Shanghai 200032, China.
出版信息
Curr Top Med Chem. 2016;16(10):1074-90. doi: 10.2174/1568026615666150901114527.
Abstract
Human immunodeficiency virus type 1 (HIV-1) envelope (Env) glycoprotein surface subunit gp120 and transmembrane subunit gp41 play important roles in HIV-1 entry, thus serving as key targets for the development of HIV-1 entry inhibitors. T20 peptide (enfuvirtide) is the first U.S. FDA-approved HIV entry inhibitor; however, its clinical application is limited by the lack of oral availability. Here, we have described the structure and function of the HIV-1 gp120 and gp41 subunits and reviewed advancements in the development of small-molecule HIV entry inhibitors specifically targeting these two Env glycoproteins. We then compared the advantages and disadvantages of different categories of HIV entry inhibitor candidates and further predicted the future trend of HIV entry inhibitor development.
摘要
人类免疫缺陷病毒1型（HIV-1）包膜（Env）糖蛋白表面亚基gp120和跨膜亚基gp41在HIV-1进入过程中发挥重要作用，因此成为开发HIV-1进入抑制剂的关键靶点。T20肽（恩夫韦肽）是美国食品药品监督管理局（FDA）批准的首个HIV进入抑制剂；然而，其临床应用因缺乏口服可用性而受到限制。在此，我们描述了HIV-1 gp120和gp41亚基的结构与功能，并综述了特异性靶向这两种Env糖蛋白的小分子HIV进入抑制剂的研发进展。然后，我们比较了不同类别HIV进入抑制剂候选物的优缺点，并进一步预测了HIV进入抑制剂的未来发展趋势。
相似文献
1
Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41.
Curr Top Med Chem. 2016;16(10):1074-90. doi: 10.2174/1568026615666150901114527.
2
Recent Progress in the Development of HIV-1 Entry Inhibitors: From Small Molecules to Potent Anti-HIV Agents.
Curr Top Med Chem. 2019;19(18):1599-1620. doi: 10.2174/1568026619666190712204050.
3
The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
FEBS J. 2015 Dec;282(24):4643-57. doi: 10.1111/febs.13541. Epub 2015 Oct 22.
4
Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41.
Viruses. 2019 Aug 1;11(8):705. doi: 10.3390/v11080705.
5
HIV-1 Entry Inhibitors: A Review of Experimental and Computational Studies.
Chem Biodivers. 2018 Oct;15(10):e1800159. doi: 10.1002/cbdv.201800159. Epub 2018 Sep 21.
6
Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
Curr Top Med Chem. 2011 Dec;11(24):2959-84. doi: 10.2174/156802611798808497.
7
A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.
J Virol. 2010 Jul;84(14):7288-99. doi: 10.1128/JVI.00535-10. Epub 2010 Apr 28.
8
Characterization of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Variants Selected for Resistance to a CD4-Mimetic Compound.
J Virol. 2022 Sep 14;96(17):e0063622. doi: 10.1128/jvi.00636-22. Epub 2022 Aug 18.
9
Strain-Dependent Activation and Inhibition of Human Immunodeficiency Virus Entry by a Specific PF-68742 Stereoisomer.
J Virol. 2019 Oct 15;93(21). doi: 10.1128/JVI.01197-19. Print 2019 Nov 1.
10
HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120.
J Virol. 2018 Jul 31;92(16). doi: 10.1128/JVI.00583-18. Print 2018 Aug 15.
引用本文的文献
1
Viral Factors in Modulation of Host Immune Response: A Route to Novel Antiviral Agents and New Therapeutic Approaches.
Int J Mol Sci. 2024 Aug 29;25(17):9408. doi: 10.3390/ijms25179408.
2
Structure-Based Identification of Natural-Product-Derived Compounds with Potential to Inhibit HIV-1 Entry.
Molecules. 2023 Jan 4;28(2):474. doi: 10.3390/molecules28020474.
3
Targeting a Conserved Lysine in the Hydrophobic Pocket of HIV-1 gp41 Improves Small Molecule Antiviral Activity.
Viruses. 2022 Dec 2;14(12):2703. doi: 10.3390/v14122703.
4
Comparative Pharmacokinetics of a Dual Inhibitor of HIV-1, NBD-14189, in Rats and Dogs with a Proof-of-Concept Evaluation of Antiviral Potency in SCID-hu Mouse Model.
Viruses. 2022 Oct 16;14(10):2268. doi: 10.3390/v14102268.
5
Novel 2-alkylthio-1-benzylimidazole-5-carboxylic Acid Derivatives Targeting Gp41: Design, Synthesis, and Anti-HIV Activity Evaluation.
Curr HIV Res. 2022;20(5):380-396. doi: 10.2174/1570162X20666220628154901.
6
Small-Molecule HIV Entry Inhibitors Targeting gp120 and gp41.
Adv Exp Med Biol. 2022;1366:27-43. doi: 10.1007/978-981-16-8702-0_3.
7
Conformational Stabilization of Gp41-Mimetic Miniproteins Opens Up New Ways of Inhibiting HIV-1 Fusion.
Int J Mol Sci. 2022 Mar 3;23(5):2794. doi: 10.3390/ijms23052794.
8
Pyrroles as Privileged Scaffolds in the Search for New Potential HIV Inhibitors.
Pharmaceuticals (Basel). 2021 Sep 2;14(9):893. doi: 10.3390/ph14090893.
9
Reduction of Progranulin-Induced Breast Cancer Stem Cell Propagation by Sortilin-Targeting Cyclotriazadisulfonamide (CADA) Compounds.
J Med Chem. 2021 Sep 9;64(17):12865-12876. doi: 10.1021/acs.jmedchem.1c00943. Epub 2021 Aug 24.
10
Anti-HIV and Anti-Candidal Effects of Methanolic Extract from .
Int J Environ Res Public Health. 2021 Jul 7;18(14):7270. doi: 10.3390/ijerph18147270.
本文引用的文献
1
Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface.
Nature. 2014 Nov 6;515(7525):138-42. doi: 10.1038/nature13601. Epub 2014 Sep 3.
2
A broad HIV-1 inhibitor blocks envelope glycoprotein transitions critical for entry.
Nat Chem Biol. 2014 Oct;10(10):845-52. doi: 10.1038/nchembio.1623. Epub 2014 Aug 31.
3
Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study.
Antimicrob Agents Chemother. 2014 Sep;58(9):5478-91. doi: 10.1128/AAC.03339-14. Epub 2014 Jul 7.
4
Structure-activity relationship studies of indole-based compounds as small molecule HIV-1 fusion inhibitors targeting glycoprotein 41.
J Med Chem. 2014 Jun 26;57(12):5270-81. doi: 10.1021/jm500344y. Epub 2014 Jun 6.
5
Crystal structures of HIV-1 gp120 envelope glycoprotein in complex with NBD analogues that target the CD4-binding site.
PLoS One. 2014 Jan 28;9(1):e85940. doi: 10.1371/journal.pone.0085940. eCollection 2014.
6
Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor.
Nat Commun. 2014;5:3067. doi: 10.1038/ncomms4067.
7
ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.
Biochim Biophys Acta. 2014 May;1838(5):1296-305. doi: 10.1016/j.bbamem.2013.12.022. Epub 2014 Jan 3.
8
Crystal structure of a soluble cleaved HIV-1 envelope trimer.
Science. 2013 Dec 20;342(6165):1477-83. doi: 10.1126/science.1245625. Epub 2013 Oct 31.
9
Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.
Antimicrob Agents Chemother. 2013 Sep;57(9):4172-80. doi: 10.1128/AAC.00513-13. Epub 2013 Jun 17.
10
Structure-Based Design and Synthesis of an HIV-1 Entry Inhibitor Exploiting X-Ray and Thermodynamic Characterization.
ACS Med Chem Lett. 2013 Mar 14;4(3):338-343. doi: 10.1021/ml300407y.
Zotero 插件